N@N

THERAVANCE, INC. (NASDAQ:THRX), Down By 16.84% ($3.64) From $21.620 After BUYINS.NET Report Predicted Stock Would Go Down Due T

^{Published on 2012-06-04 11:40:42 - WOPRAI}
 

June 4, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, May 16th 2012 stating that THERAVANCE, INC. (NASDAQ:THRX) was expected to go Down due to the Bearish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=thrx&id=275338

At the time this story was written, THERAVANCE, INC. (NASDAQ:THRX) is Down By $3.64 (16.84%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

THERAVANCE, INC. (NASDAQ:THRX) - Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines across various therapeutic areas, including respiratory disease, bacterial infections, and gastrointestinal motility dysfunction. Its key programs include VIBATIV with Astellas Pharma, Inc. approved in the United States and Canada for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant and methicillin-susceptible strains; RELOVAIR with GlaxoSmithKline (GSK), a Phase 3 clinical trial program for the treatment of patients with chronic obstructive pulmonary disease and/or asthma; and the Bifunctional Muscarinic Antagonist-beta2 Agonist program with GSK, which completed Phase 2a. The companys other pipeline programs under various clinical-stages comprise TD-1211, an oral peripheral Mu-opioid antagonist for the treatment of opioid-induced constipation; TD-5108 and TD-8954, 5HT-4 agonists for the treatment of gastrointestinal motility dysfunction and/or Alzheimers disease; TD-1792, an antibiotic for the treatment of serious infections caused by Gram-positive bacteria; and MARIN program (TD-9855) for the treatment of chronic pain. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance was founded in 1996 and is headquartered in South San Francisco, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net